<DOC>
	<DOCNO>NCT00004934</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether receive paclitaxel carboplatin epirubicin effective paclitaxel carboplatin alone ovarian epithelial , fallopian tube , peritoneal cancer . PURPOSE : Randomized phase III trial compare effectiveness paclitaxel carboplatin without epirubicin treat patient stage IIB , stage III , stage IV invasive ovarian epithelial , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin With Without Epirubicin Treating Patients With Stage IIB , Stage III , Stage IV Invasive Ovarian Epithelial , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression free survival overall survival patient stage IIB , III , IV invasive ovarian epithelial , fallopian tube , peritoneal cancer treat paclitaxel carboplatin without epirubicin . - Compare toxicity 2 regimens patient . - Compare quality life patient treat 2 regimen . OUTLINE : This randomize , multicenter study . Patients stratify center type surgery ( delay surgery : 3 course chemotherapy surgery v primary surgery : optimally debulked stage IIB III [ residual tumor le 1 cm ] v primary surgery : suboptimally debulked stage IV [ residual tumor 1 cm great ] ) . Surgery - Patients assign one two surgery group : - Group A : Patients undergo primary surgery comprise hysterectomy , bilateral salpingo-oophorectomy ( BSO ) , omentectomy , resection tumor mass , possible , begin chemotherapy . Patients residual disease great 1 cm completion primary surgery receive 3 course chemotherapy , follow within 6 week interval debulking surgery , follow within 3 week fourth course chemotherapy . - Group B : Patients undergo delay surgery comprised hysterectomy , BSO , omentectomy , resection tumor mass , possible , completion 3 course chemotherapy . Chemotherapy - Patients randomize 1 2 chemotherapy arm : - Arm I : Patients receive epirubicin IV 15-20 minute , paclitaxel IV 3 hour , carboplatin IV 1 hour day 1 . Treatment repeat every 3 week 6 course . Patients residual tumor completion 6 course may receive 3 additional course . - Arm II : Patients receive paclitaxel carboplatin epirubicin . Quality life assess begin study , completion course 3 , 6 , 9 ( applicable ) , 6 12 month completion study treatment . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 800 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIB , III , IV invasive ovarian epithelial , fallopian tube , peritoneal cancer No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO/ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal Renal : Glomerular filtration rate least 50 mL/min Cardiovascular : No ventricular arrhythmia ( LOWN class II worse ) No myocardial infarction within past year No severe uncontrolled hypertension No history congestive heart disease ( New York Heart Association class III IV heart disease ) even medically control LVEF least 50 % Other : No primary malignancy except carcinoma situ cervix basal cell skin cancer No bad grade I preexist motor sensory neurologic pathology symptom No active infection serious underlie medical condition would prevent compliance Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent antineoplastic agent Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>